Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the 'pan-European registry collaboration for abatacept (PANABA).

MLA

Iannone, Florenzo, et al. “Body Mass Does Not Impact the Clinical Response to Intravenous Abatacept in Patients with Rheumatoid Arthritis. Analysis from the ’pan-European Registry Collaboration for Abatacept (PANABA).” Clinical Rheumatology, vol. 36, no. 4, Apr. 2017, pp. 773–79. EBSCOhost, https://doi.org/10.1007/s10067-016-3505-5.

APA

Iannone, F., Courvoisier, D., Gottenberg, J., Hernandez, M., Lie, E., Canhão, H., Pavelka, K., Hetland, M., Turesson, C., Mariette, X., Choquette, D., & Finckh, A. (2017). Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the ’pan-European registry collaboration for abatacept (PANABA). Clinical Rheumatology, 36(4), 773–779. https://doi.org/10.1007/s10067-016-3505-5

Chicago

Iannone, Florenzo, Delphine Courvoisier, Jacques Gottenberg, Maria Hernandez, Elisabeth Lie, Helena Canhão, Karel Pavelka, et al. 2017. “Body Mass Does Not Impact the Clinical Response to Intravenous Abatacept in Patients with Rheumatoid Arthritis. Analysis from the ’pan-European Registry Collaboration for Abatacept (PANABA).” Clinical Rheumatology 36 (4): 773–79. doi:10.1007/s10067-016-3505-5.